RE: GXO - Takeover interest + exploring sale10 Oct 2024 14:33
Yes Steve, nutrition numbers have gone backwards, but there’s been the rebrand and they’ve dialled back customer acquisition in less profitable markets. It’s still a good, cash generative business, suited to a d2c model, with a lot of repeat customers. It remains a valuable asset, even with spot whey prices ticking up (which I know you get very excited about). Back in growth in September, let’s see what MM says about the outlook. I’m optimistic about Nutritions future with the “My” branding, some clever partnerships/product innovation with some big names pushing it into the mainstream, and of course the push into offline.
Anyway, all eyes on the Ingenuity demerger which is what really matters at the moment. You’ve said Ingenuity is a valueless cash drain for a long time, but looks to me like the BoD think they can successfully get a demerger away. £600m t/o (you can’t write off internal revenue as irrelevant once it’s demerged), recurring “sticky” revenue, fully invested infrastructure and automation with excess capacity, improving EBITDA margins and only £150m of investment required to get it to cash generative. Oh, and EBIDTA margins are improving nicely with all the automation, and will only improve as the infrastructure gets fully utilised. Doesn’t look like a worthless cash drain to me.